12 Month Price Forecast For AORT
Distance to AORT Price Forecasts
AORT Price Momentum
🤔 Considering Artivion (AORT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 7:54 AM UTC
AORT Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, AORT has a consensus that is bullish. The median price target is $33.00, with forecasts ranging from $32.00 to $35.00. Currently, there are 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With AORT currently trading at $29.50, the median price forecast suggests a 11.9% upside. The most optimistic forecast comes from at , projecting a 18.6% upside, while Suraj Kalia at Oppenheimer provides the most conservative target, suggesting a 8.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AORT Analyst Consensus
AORT Price Target Range
Latest AORT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AORT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 8, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $32.00 |
| Oct 23, 2024 | JMP Securities | Daniel Stauder | Market Outperform | Initiates | $33.00 |
| Sep 27, 2024 | Needham | Mike Matson | Buy | Reiterates | $30.00 |
| Sep 13, 2024 | Stifel | Rick Wise | Buy | Maintains | $30.00 |
| Aug 9, 2024 | Stifel | Rick Wise | Buy | Maintains | $28.00 |
| Aug 9, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $30.00 |
| Aug 9, 2024 | Needham | Mike Matson | Buy | Reiterates | $30.00 |
| Jul 2, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $30.00 |
| May 7, 2024 | Stifel | Rick Wise | Buy | Maintains | $25.00 |
| May 7, 2024 | Needham | Mike Matson | Buy | Maintains | $30.00 |
| Apr 8, 2024 | Needham | Mike Matson | Buy | Maintains | $25.00 |
| Feb 16, 2024 | Stifel | Rick Wise | Buy | Maintains | $22.00 |
| Feb 16, 2024 | Needham | Mike Matson | Buy | Maintains | $25.00 |
| Dec 7, 2023 | Needham | Mike Matson | Buy | Reiterates | $22.00 |
| Nov 3, 2023 | Needham | Mike Matson | Buy | Maintains | $22.00 |
| Aug 4, 2023 | Needham | Mike Matson | Buy | Reiterates | $26.00 |
| May 8, 2023 | Morgan Stanley | Cecilia Furlong | Equal-Weight | Maintains | $15.00 |
| May 5, 2023 | Needham | Mike Matson | Buy | Maintains | $26.00 |
| Feb 17, 2023 | Needham | Mike Matson | Buy | Maintains | $23.00 |
| Nov 4, 2022 | Needham | Mike Matson | Buy | Maintains | $23.00 |
Artivion, Inc. (AORT) Financial Data
Artivion, Inc. has a market capitalization of $1.24B with a P/E ratio of -39.3x. The company generates $384.90M in trailing twelve-month revenue with a -0.2% profit margin.
Revenue growth is +9.0% quarter-over-quarter, while maintaining an operating margin of +8.3% and return on equity of -0.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Artivion, Inc. (AORT) Company Overview
About Artivion, Inc.
Manufactures medical devices and human tissues.
The company generates revenue through the manufacture, processing, and distribution of various medical devices and implantable tissues. It offers a range of products including BioGlue, stent grafts, synthetic vascular grafts, and other surgical tools, catering primarily to healthcare facilities and surgeons globally.
Artivion, Inc. was originally established as CryoLife, Inc. in 1984 and rebranded in January 2022. It is headquartered in Kennesaw, Georgia, and serves a diverse clientele including physicians and hospitals, focusing on cardiac, vascular, and thoracic surgical needs.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,500
CEO
Mr. James Patrick Mackin
Country
United States
IPO Year
1993
Website
artivion.comArtivion, Inc. (AORT) Latest News & Analysis
US medical device giant Artivion says hackers stole files during cybersecurity incident
4 days agoArtivion reports a cybersecurity incident that has disrupted its services in manufacturing implantable tissues for cardiac and vascular applications.
Artivion's cybersecurity incident could lead to operational delays, financial losses, and potential regulatory scrutiny, impacting investor confidence and stock performance.
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis
4 days agoArtivion, Inc. (NYSE: AORT) received FDA approval for the AMDS Hybrid Prosthesis, the first device for treating acute DeBakey Type I aortic dissections with malperfusion.
FDA approval of Artivion's AMDS Hybrid Prosthesis enhances its market position and potential revenue, signaling growth opportunities in the cardiac device sector.
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript
1 month agoArtivion, Inc. (NYSE:AORT) will hold its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.
The earnings call provides insights into Artivion's financial performance and strategic direction, influencing investor sentiment and stock price volatility.
Artivion Reports Third Quarter 2024 Financial Results
1 month agoIn Q3 2024, revenue rose 9% to $95.8M; net loss was $2.3M. Adjusted EBITDA increased 28% to $17.7M. FDA PMA application submitted for AMDS Hybrid Prosthesis; BioGlue approved for China, commercialization in 2025.
Revenue growth of 9% signals strong demand. Regulatory approvals enhance future prospects, while improved EBITDA suggests operational efficiency. Net loss raises caution but overall positive outlook.
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates
1 month agoArtivion (AORT) reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.03 and up from $0.02 per share in the previous year.
Artivion's strong earnings beat signals improved financial health and growth potential, which may boost investor confidence and positively impact stock performance.
Artivion to Participate in Upcoming Investor Conferences
1 month agoArtivion, Inc. (NYSE: AORT) will present at the Stifel 2024 Healthcare Conference on November 19, 2024, in New York, highlighting its focus on aortic disease.
Artivion's participation in investor conferences can enhance visibility, attract interest, and potentially influence stock price by providing insights into company performance and future prospects.
Frequently Asked Questions About AORT Stock
What is Artivion, Inc.'s (AORT) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Artivion, Inc. (AORT) has a median price target of $33.00. The highest price target is $35.00 and the lowest is $32.00.
Is AORT stock a good investment in 2025?
According to current analyst ratings, AORT has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for AORT stock?
Wall Street analysts predict AORT stock could reach $33.00 in the next 12 months. This represents a 11.9% increase from the current price of $29.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Artivion, Inc.'s business model?
The company generates revenue through the manufacture, processing, and distribution of various medical devices and implantable tissues. It offers a range of products including BioGlue, stent grafts, synthetic vascular grafts, and other surgical tools, catering primarily to healthcare facilities and surgeons globally.
What is the highest forecasted price for AORT Artivion, Inc.?
The highest price target for AORT is $35.00 from at , which represents a 18.6% increase from the current price of $29.50.
What is the lowest forecasted price for AORT Artivion, Inc.?
The lowest price target for AORT is $32.00 from Suraj Kalia at Oppenheimer, which represents a 8.5% increase from the current price of $29.50.
What is the overall AORT consensus from analysts for Artivion, Inc.?
The overall analyst consensus for AORT is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $33.00.
How accurate are AORT stock price projections?
Stock price projections, including those for Artivion, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
